¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"organic reaction type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • indirect immunofluorescence reaction
    °£Á¢¸é¿ªÇü±¤¹ÝÀÀ
  • indophenol reaction
    ÀεµÆä³î°Ë»ç
  • induced reaction
    À¯¹ß¹ÝÀÀ
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
  • interface reaction
    °æ°è¸é¹ÝÀÀ
  • intermediate reaction
    Áß°£¹ÝÀÀ
  • intermicellar reaction
    ¹Ì¼¼¸£°£¹ÝÀÀ
  • Jarisch-Herxheimer reaction
    ¾ß¸®½´-Ç츣ũ½ºÇÏÀ̸ӹÝÀÀ
  • johnin reaction
    ¿ä´Ñ¹ÝÀÀ
  • labile oxidase reaction
    ºÒ¾ÈÁ¤»êÈ­È¿¼Ò¹ÝÀÀ
  • lengthening reaction
    1. ´ÃÀÓ¹ÝÀÀ, ½ÅÀå¹ÝÀÀ 2. ±Ù´ÃÀÓ¹ÝÀÀ
  • lepra reaction
    ³ªº´¹ÝÀÀ
  • lepromin reaction
    ·¹ÇÁ·Î¹Î¹ÝÀÀ
  • leukemoid reaction
    ¹éÇ÷º´¸ð¾ç¹ÝÀÀ
  • leukoerythroblastic reaction
    ¹éÀûÇ÷¸ð±¸¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • fuchsinophil reaction
    Ç«½Åģȭ¹ÝÀÀ
  • reaction fever
    ¹ÝÀÀ¿­
  • reaction formation
    ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º
  • gel diffusion precipitin reaction
    ¿ì¹«È®»êħÀü¹ÝÀÀ
  • gluteal reaction
    º¼±â¹ÝÀÀ
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ
  • grief reaction
    ¾Öµµ¹ÝÀÀ, ºñ¾Ö¹ÝÀÀ
  • gross stress reaction
    ´ëÀڱعÝÀÀ, ÃÑüÀû½ºÆ®·¹½º¹ÝÀÀ
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • hemoclastic reaction
    Ç÷±¸ºØ±«¹ÝÀÀ
  • hemolytic transfusion reaction
    ¿ëÇ÷¼öÇ÷¹ÝÀÀ
  • Herxheimer¡¯s reaction
    (¢¡Jarisch-Herxheimer reaction) ¾ß¸®½ÃÇ츤½ºÇÏÀ̸ӹÝÀÀ
  • heterogeneous reaction
    ºÒ±ÕÀϹÝÀÀ, ºÒ±ÕÁú¹ÝÀÀ
  • heterophil antibody reaction
    ÀÌÁ¾Ä£È­Ç×ü¹ÝÀÀ
  • homograft reaction
    µ¿Á¾À̽ĹÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • primitive reaction
    ¿ø½Ã¹ÝÀÀ(¡­Úãëë).
  • principal reaction
    ÁÖ¹ÝÀÀ(ñ«Úãëë).
  • prolonged depressive reaction
    Áö¼ÓÀû¡¡¿ì¿ï¹ÝÀÀ
  • protracted reaction
    Áö¿¬¹ÝÀÀ(òÀæÅÚãëë).
  • prussian blue reaction
    °¨Ã»¹ÝÀÀ
  • psychogenic reaction
    ½ÉÀμº ¹ÝÀÀ(¡­Úãëë).
  • psychotic depressive reaction
    Á¤½ÅÁõÀû ¿ì¿ï¹ÝÀÀ(éØê¦Úãëë).
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ.
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ(Û¡æðÚãëë)
  • pyrrole reaction
    ÇǷѹÝÀÀ(¡­Úãëë).
  • quellung reaction
    ÆØÃ¢¹ÝÀÀ(ø³óìÚãëë).
  • rage reaction
    ³ë¹ÝÀÀ(ÖÍÚãëë).
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ.
  • reaction accelerator
    ¹ÝÀÀÃËÁøÃ¼(Úãëë õµòäô÷).
  • reaction center
    Ȱ¼ºÁß½É(üÀàõñéãý).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • onion skin type
    ¾çÆÄ²®Áú¸ð¾ç
  • ovulatory type
    ¹è¶õÇü
  • particle, C-type
    CÇü ÀÔÀÚ (·¹Æ®·Î¹ÙÀÌ·¯½ºÀÇ)
  • personality disorder, mixed type
    È¥ÀçÇü(ûèî¤úþ) ÀΰÝÀå¾Ö
  • personality, type A
    AÇü ÀΰÝ
  • personality, type B
    BÇü ÀΰÝ
  • phage type
    ÆÄÁöÇü
  • phage type
    ÆÄÁöÇü(¡­úþ).
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
  • phased linear array type
    À§»óÂ÷ ¼±Çü ¹è¿­½Ä
  • phthisic type
    ³ëÁõº¸Çü( ñøÜÁúþ).
  • phthisic type
    ³ëÁõº¸Çü(Ò¾ñøÜÁúþ)
  • pilus, type 1
    Á¦1Çü ¼¶¸ð
  • plaque-type mutation
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • platelet-type
    Ç÷¼ÒÆÇÇü(û¡)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
ATCC American Type Culture Collection
ATD Alzheimer-type dementia; androstatrienedione; anthropomorphic test dummy; antithyroid drug; aqueous ...
beta [Greek letter beta] an anomer of a carbohydrate; buffer capacity; carbon separated from a carboxyl by one other carbon i...
BHK baby hamster kidney [cells]; type-B Hong Kong [influenza virus]
BlT bleeding time; blood test; blood type, blood typing
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
PCR-SSCP Polymerase chain reaction and single strand conformation polymorphism
PCR Polymerase chain reaction assay
PCR-SSO Polymerase chain reaction sequence-specific oligonucleotide
PCR-SSCP Polymerase chain reaction single strand conformational polymorphism
PCR-SSP Polymerase chain reaction with sequence specific primers
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • reaction formation
    ¹Ýµ¿ Çü¼º
    ¾ïÁ¦µÈ ¹Ý»çȸÀûÀÎ Ãæµ¿°ú´Â »ó¹ÝµÇ°í ¶ÇÇÑ ±×°ÍÀÇ ´ë½ÅÀÌ µÇ´Â ¾î¶² ŵµ¸¦ ¹«ÀǽÄÀûÀ¸·Î ÃëÇÏ°Ô µÇ´Â Á¤½Å ±â±¸.
  • reaction of identity
    ÀÏÄ¡ ¹ÝÀÀ
  • reaction of partial identity
    ºÎºÐ ÀÏÄ¡ ¹ÝÀÀ
  • reaction threshold
    ¹ÝÀÀ ¿ªÄ¡
    ÀÚ±ØÀ» ÁØ ÈÄ ¹ÝÀÀÀÌ ÀϾ±â±îÁöÀÇ °ª.
  • reversible reaction
    °¡¿ª ¹ÝÀÀ
  • scratch reaction
    ¼ÒÆÄ ¹ÝÀÀ
    Áï½ÃÇü ¾Ë·¯Áö ÁúȯÀÇ Áø´Ü¹ý.
  • serologic reaction
    Ç÷û ¹ÝÀÀ, Ç÷ûÇÐÀû ¹ÝÀÀ
  • serum colloidal reaction
    Ç÷û ±³Áú ¹ÝÀÀ
    °£ ±â´É °Ë»çÀÇ Á¾·ù.
  • serum reaction
    Ç÷û ¹ÝÀÀ
    Ç׿ø Ç×ü ¹ÝÀÀÀ» ½ÃÇè°ü ³»¿¡¼­ ÀçÇöÇÒ ¼ö ÀÖ´Â ¹ÝÀÀ.
  • shock circuit reaction
    ´Ü¶ô ¹ÝÀÀ
    °¨Á¤Àû Ãæµ¿ÀÌ À̼ºÀÇ ÅëÁ¦¸¦ ¹þ¾î³ª Á÷Á¢À¸·Î Çൿ¿¡ ¿Å°ÜÁö´Â ¹ÝÀÀ.
  • side reaction
    ºÎÀÛ¿ë, ºÎ¹ÝÀÀ
  • skin reaction
    ÇǺΠ¹ÝÀÀ
  • successive reaction
    ¹Ýº¹ ¹ÝÀÀ
  • toxic reaction
    µ¶ ¹ÝÀÀ, Áßµ¶ ¹ÝÀÀ
  • toxin antitoxin reaction
    µ¶¼Ò-Ç×µ¶¼Ò ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
type III acrocephalosyndactyly An autosomal dominant syndrome with variable expression of brachycephaly, maxillary hypoplasia, prominent ear crus, syndactyly, facial asymmetry, shallow orbits, telecanthus, and nasal septal deviation; may show mental retardation.
Synonym: Saethre-Chotzen syndrome.
(05 Mar 2000)
type III collagen Collagen characteristic of reticular fibres.
(05 Mar 2000)
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
type IV collagen A less distinctly fibrillar form of collagen characteristic of basement membranes.
(05 Mar 2000)
type IV familial hyperlipoproteinaemia Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance.
Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
ÅëÇÕ°Ë»ö ¿Ï·á